Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 3
2009 2
2010 2
2011 4
2013 5
2014 2
2015 2
2016 5
2017 3
2018 4
2019 1
2020 2
Text availability
Article attribute
Article type
Publication date

Search Results

30 results
Results by year
Filters applied: . Clear all
Page 1
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, Janssen JJWM, Mayer J, Koskenvesa P, Panayiotidis P, Olsson-Strömberg U, Martinez-Lopez J, Rousselot P, Vestergaard H, Ehrencrona H, Kairisto V, Machová Poláková K, Müller MC, Mustjoki S, Berger MG, Fabarius A, Hofmann WK, Hochhaus A, Pfirrmann M, Mahon FX; EURO-SKI investigators. Saussele S, et al. Among authors: machova polakova k. Lancet Oncol. 2018 Jun;19(6):747-757. doi: 10.1016/S1470-2045(18)30192-X. Epub 2018 May 4. Lancet Oncol. 2018. PMID: 29735299 Clinical Trial.
BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.
Srutova K, Curik N, Burda P, Savvulidi F, Silvestri G, Trotta R, Klamova H, Pecherkova P, Sovova Z, Koblihova J, Stopka T, Perrotti D, Polakova KM. Srutova K, et al. Among authors: polakova km. Haematologica. 2018 Dec;103(12):2016-2025. doi: 10.3324/haematol.2018.193086. Epub 2018 Jul 26. Haematologica. 2018. PMID: 30049824 Free PMC article.
miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels.
Musilova K, Devan J, Cerna K, Seda V, Pavlasova G, Sharma S, Oppelt J, Pytlik R, Prochazka V, Prouzova Z, Trbusek M, Zlamalikova L, Liskova K, Kruzova L, Jarosova M, Mareckova A, Kornauth C, Simonitsch-Klupp I, Schiefer AI, Merkel O, Mocikova H, Burda P, Machova Polakova K, Kren L, Mayer J, Zent CS, Trneny M, Evans AG, Janikova A, Mraz M. Musilova K, et al. Among authors: machova polakova k. Blood. 2018 Nov 29;132(22):2389-2400. doi: 10.1182/blood-2018-06-855502. Epub 2018 Sep 13. Blood. 2018. PMID: 30213873
Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology.
Hovorkova L, Zaliova M, Venn NC, Bleckmann K, Trkova M, Potuckova E, Vaskova M, Linhartova J, Machova Polakova K, Fronkova E, Muskovic W, Giles JE, Shaw PJ, Cario G, Sutton R, Stary J, Trka J, Zuna J. Hovorkova L, et al. Among authors: machova polakova k. Blood. 2017 May 18;129(20):2771-2781. doi: 10.1182/blood-2016-11-749978. Epub 2017 Mar 22. Blood. 2017. PMID: 28331056
Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry).
Möbius S, Schenk T, Himsel D, Maier J, Franke GN, Saussele S, Pott C, Andrikovics H, Meggyesi N, Machova-Polakova K, Zizkova H, Jurcek T, Mesanovic S, Zadro R, Gottardi E, Haenig J, Schuld P, Cross NCP, Hochhaus A, Ernst T. Möbius S, et al. Among authors: machova polakova k. J Cancer Res Clin Oncol. 2019 Jun;145(6):1645-1650. doi: 10.1007/s00432-019-02910-6. Epub 2019 Apr 2. J Cancer Res Clin Oncol. 2019. PMID: 30941573
AFLP-AFLP in silico-NGS approach reveals polymorphisms in repetitive elements in the malignant genome.
Koblihova J, Srutova K, Krutska M, Klamova H, Machova Polakova K. Koblihova J, et al. Among authors: machova polakova k. PLoS One. 2018 Nov 8;13(11):e0206620. doi: 10.1371/journal.pone.0206620. eCollection 2018. PLoS One. 2018. PMID: 30408048 Free PMC article.
Role of epigenetics in chronic myeloid leukemia.
Machova Polakova K, Koblihova J, Stopka T. Machova Polakova K, et al. Curr Hematol Malig Rep. 2013 Mar;8(1):28-36. doi: 10.1007/s11899-012-0152-z. Curr Hematol Malig Rep. 2013. PMID: 23296408 Free PMC article. Review.
Expression of genes encoding centrosomal proteins and the humoral response against these proteins in chronic myeloid leukemia.
Šmahelová J, Kaštánková I, Poláková KM, Klamová H, Zemanová K, Tachezy R, Hamšíková E, Šmahel M. Šmahelová J, et al. Among authors: polakova km. Oncol Rep. 2017 Jan;37(1):547-554. doi: 10.3892/or.2016.5226. Epub 2016 Nov 7. Oncol Rep. 2017. PMID: 27840977
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.
Soverini S, De Benedittis C, Polakova KM, Linhartova J, Castagnetti F, Gugliotta G, Papayannidis C, Mancini M, Klamova H, Salvucci M, Crugnola M, Iurlo A, Albano F, Russo D, Rosti G, Cavo M, Baccarani M, Martinelli G. Soverini S, et al. Among authors: polakova km. Oncotarget. 2016 Apr 19;7(16):21982-90. doi: 10.18632/oncotarget.8010. Oncotarget. 2016. PMID: 26980736 Free PMC article.
Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment.
Jaruskova M, Curik N, Hercog R, Polivkova V, Motlova E, Benes V, Klamova H, Pecherkova P, Belohlavkova P, Vrbacky F, Machova Polakova K. Jaruskova M, et al. Among authors: machova polakova k. J Exp Clin Cancer Res. 2017 Apr 18;36(1):55. doi: 10.1186/s13046-017-0523-3. J Exp Clin Cancer Res. 2017. PMID: 28420426 Free PMC article.
30 results
Jump to page
Feedback